GR-MD-02: Keytruda’s Partner

● Tumors excrete elevated level of galectin-3 ● Galectin-3 diminishes T-cells’ ability to kill tumor cells ● Galectin-3 aids in cancer progression ● GR-MD-02 is safe, effective, and inexpensive, potentially becoming possible new standard immunotherapy used with Keytruda.

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. However, FINRA regulations require all readers to sign onto our site. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.

2 COMMENTS

LEAVE A REPLY